Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive VA study to settle debate: which blood thinner is safer for A-Fib?

NCT ID NCT06953726

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare two widely used blood thinners, apixaban (Eliquis) and rivaroxaban (Xarelto), in about 10,000 veterans with atrial fibrillation (an irregular heartbeat). The goal is to see which drug better prevents strokes and major bleeding. Participants must already be taking one of these medications, and all data will be collected from medical records over about 7 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Oct 2033

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Male or female Veteran, aged 22 years or older 2. Diagnosis of atrial fibrillation (AF) or atrial flutter (AFL) and currently taking either apixaban or rivaroxaban. 3. CHA2DS2-Vasc of 3 or more 4. Ability to take oral medication and self-reported willingness to adhere to the prespecified apixaban or rivaroxaban regimen Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study; notably use of antiplatelet agents or prior OAC use will not be an exclusion criterion: 1. Current use of oral or injectable anticoagulation, without ability to switch to the assigned study medication 2. Another indication for anticoagulation, such as pulmonary embolism 3. Contraindication to oral anticoagulation 4. Known bleeding diathesis 5. Documented current pregnancy or lactation in the EHR or self-reported current pregnancy or lactation 6. Known allergic reactions or intolerance to apixaban or rivaroxaban 7. Most recent estimated glomerular filtration rate (eGFR) is \< 30 mL/minute/1.73m2. An eGFR result must have been obtained within 18 months before randomization. 8. Known mechanical heart valve 9. Known moderate-severe mitral stenosis 10. Known history of left atrial occlusion, excision, or ligation 11. Current or planned use of systemic ritonavir, itraconazole, or ketoconazole (topical use of ketoconazole only is allowed) 12. Cardiac or thoracic surgery in the past 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial flutter Hemorrhage Ischemic Stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Boston VA CSP Coordinating Center

    RECRUITING

    Boston, Massachusetts, 02111, United States

  • Miami VA Healthcare System, Miami, FL

    RECRUITING

    Miami, Florida, 33125, United States

  • Minneapolis VA Call Center

    RECRUITING

    Minneapolis, Minnesota, 55417, United States

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02130-4817, United States

  • VA Portland Health Care System, Portland, OR

    RECRUITING

    Portland, Oregon, 97207-2964, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.